ASCO: ALEX trial results show alectinib further outpacing crizotinib in ALK+ NSCLC
Credit: University of Colorado Cancer Center Updated results of the global phase III ALEX trial comparing alectinib with crizotinib as first-line treatment against ALK-positive non-small...







